Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
about
Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cellsRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesDual neonate vaccine platform against HIV-1 and M. tuberculosis.Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challengesThe use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigenPre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesA phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infantsEngineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCGPedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in MiceRobust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques.Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors
P2860
Q28730854-03773217-AC06-48C8-99D4-C4B260521C53Q30387447-19362C1B-5B27-4537-82CA-F9394422A767Q30485791-C1C63EE3-5470-4397-BA12-356F9A78E4E1Q33584559-21FBA241-6C78-45FF-ACBF-A60664B6AE90Q33877458-5337496A-54B4-46B6-9B56-06E6CBD90EC7Q33908584-1CB4816E-0DE1-4721-BC33-8F44C66C8395Q33916635-5EFCD707-1BD5-4CA6-BD09-0185DF3F7C7CQ33952259-BFDAFDDE-3E98-4348-9DBB-AFC057F61CEAQ34395523-54C7860A-D362-498C-807E-03F4A35E1175Q34971570-C0B598F4-A127-4ED5-A811-AE2E90D17843Q34983688-1CABF684-6E18-403D-8759-35F4CF8F3671Q35036289-CF8D8E11-242D-4F31-9627-29A351C798B2Q35184235-F959A01F-CF0A-4E17-B518-25195F7D4738Q35554825-FA0D8D62-AA34-4060-AD69-6C9EA464B5DAQ35940744-37399E4A-A2B3-4DA7-93D2-0480D95EB247Q36079913-02BE350C-F6D8-4890-95CE-FFF5789A4F5BQ36759963-346755ED-783A-4546-9ED4-B9E8E2C7B77FQ37490057-48348A78-E921-4AB9-A476-ADF4A18EDFC6Q37563616-EF3A96A2-74F8-4DD3-8285-D6016C2B3D14Q40234787-1F62A2F2-576F-4003-B65C-1CD8A54CF48BQ42165676-7E73555B-13DE-4C54-9468-F4ED88B2C555Q42738025-D6D78E34-3BC3-4957-B042-58F071C3326FQ57078025-2F97D862-76BE-4DE8-9140-CB474965881B
P2860
Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vaccine platform for preventio ...... type 1 through breastfeeding.
@ast
Vaccine platform for preventio ...... type 1 through breastfeeding.
@en
type
label
Vaccine platform for preventio ...... type 1 through breastfeeding.
@ast
Vaccine platform for preventio ...... type 1 through breastfeeding.
@en
prefLabel
Vaccine platform for preventio ...... type 1 through breastfeeding.
@ast
Vaccine platform for preventio ...... type 1 through breastfeeding.
@en
P2093
P2860
P356
P1433
P1476
Vaccine platform for preventio ...... type 1 through breastfeeding.
@en
P2093
Clare Sander
Denise Teoh
Eung-Jun Im
Goretti Virgili
Joan Joseph
Jose M Gatell
Narcís Saubi
Tomás Hanke
P2860
P304
P356
10.1128/JVI.00707-07
P407
P577
2007-06-27T00:00:00Z